Skip to main content
SpringerLink
Log in

Thiazolidinediones for the Therapeutic Management of Polycystic Ovary Syndrome

Impact on Metabolic and Reproductive Abnormalities

  • Review Article
  • Published:
Treatments in Endocrinology

Abstract

Polycystic ovary syndrome (PCOS) is a diagnosis made between late adolescence and the menopause in 5–10% of women. PCOS is a heterogeneous disorder of unknown etiology characterized by hyperandrogenic chronic anovulation. This syndrome consists of a diverse constellation of signs and symptoms, such as hirsutism, acne, acanthosis nigricans, obesity, menstrual irregularities, anovulation, and/or infertility. Features of the metabolic syndrome, including obesity, insulin resistance, and dyslipidemia, are common in this patient population. Recent insights into the pathophysiology of PCOS have shown insulin resistance and hyperinsulinemia to play a substantial role. Insulin resistance is increasingly recognized as a chronic, low-level, inflammatory state. Recent studies show that serum levels of inflammatory mediators, such as tumor necrosis factor-α and interleukin-6, are increased in the insulin-resistant conditions of obesity and PCOS. The optimal modality for long-term treatment should have positive effects on androgen synthesis, sex hormone-binding globulin production, the lipid profile, insulin sensitivity, inflammatory mediators, and clinical symptoms including acne, hirsutism, and irregular menstrual cycles. Treatment with insulin-sensitizing agents is a relatively new therapeutic strategy in women with PCOS. Current research has shown that the use of diabetes mellitus management practices aimed at reducing insulin resistance and hyperinsulinemia (such as weight reduction and the administration of oral antidiabetic drugs) can not only reverse testosterone and luteinizing hormone abnormalities and restore menstrual cycles, but can also improve glucose, insulin, proinflammatory cytokine, and lipid profiles.

Clinical treatment with troglitazone, a member of the thiazolidinedione family, for the management of PCOS complications such as insulin resistance, hyperandrogenism, and anovulation was found to have beneficial effects; however, it was taken off the market over concerns of hepatotoxicity. Although troglitazone is no longer available in the US, numerous clinical trials have established the role of thiazolidinediones in the treatment of women with PCOS. Clinical data emerging regarding the utility of two of the newer, safer thiazolidinediones, pioglitazone and rosiglitazone, for this patient population, consistently demonstrate effective improvements of endocrine and ovulatory performance in women with PCOS. The benefit and importance of lifestyle modification and weight reduction, when it can be achieved, is still an important component in the long-term treatment of PCOS. Pharmacologic reduction in insulin levels using thiazolidinediones appears to offer another therapeutic modality for PCOS, which may ameliorate the progress of both hyperinsulinemia and hyperandrogenism. However, additional studies of patients so treated are necessary before these agents can be considered first-line treatment for PCOS. Convincing data from randomized controlled trials with sufficient power to detect both the benefits and risks of long-term treatment with thiazolidinediones in women with PCOS remain to be obtained.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Table I

Similar content being viewed by others

References

  1. Stein I, Leventhal M. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935; 29: 181–91

    Google Scholar 

  2. Knochenhauer ES, Key TJ, Kahsar-Miller M, et al. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998; 83: 3078–82

    Article  PubMed  CAS  Google Scholar 

  3. Rodin DA, Bano G, Bland JM, et al. Polycystic ovaries and associated metabolic abnormalities in Indian subcontinent Asian women. Clin Endocrinol (Oxf) 1998; 49: 91–9

    Article  CAS  Google Scholar 

  4. Asuncion M, Calvo RM, San Millan JL, et al. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000; 85: 310–4

    Article  Google Scholar 

  5. Wijeyaratne CN, Baien AH, Barth JH, et al. Clinical manifestations and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among South Asians and Caucasians: is there a difference? Clin Endocrinol (Oxf) 2002; 57: 343–50

    Article  CAS  Google Scholar 

  6. Franks S. Adult polycystic ovary syndrome begins in childhood. Best Pract Res Clin Endocrinol Metab 2002; 16(2): 263–72

    Article  PubMed  Google Scholar 

  7. Franks S. Polycystic ovary syndrome. N Engl J Med 1995; 333: 853–61

    Article  PubMed  CAS  Google Scholar 

  8. Rosenfield RL. Current concepts of polycystic ovary syndrome. Baillieres Clin Obstet Gynaecol 1997; 11(2): 307–33

    Article  PubMed  CAS  Google Scholar 

  9. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005; 352: 1223–6

    Article  PubMed  CAS  Google Scholar 

  10. Hollmann M, Runnebaum B, Gerhard I. Effects of weight loss on the hormonal profile in obese, infertile women. Hum Reprod 1996; 11: 1884–91

    Article  PubMed  CAS  Google Scholar 

  11. Azziz R, Ehrmann D, Legro RS, et al. PCOS/Troglitazone Study Group: troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2001; 86: 1626–32

    Article  PubMed  CAS  Google Scholar 

  12. Carmina E, Legro RS, Stamets K, et al. Difference in body weight between American and Italian women with polycystic ovary syndrome: influence of the diet. Hum Reprod 2003; 10: 267–80

    Google Scholar 

  13. Kirchengast S, Huber J. Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Hum Reprod 2001; 16: 1255–60

    Article  PubMed  CAS  Google Scholar 

  14. Glueck CJ, Papanna R, Wang P, et al. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism 2003; 52: 908–15

    Article  PubMed  CAS  Google Scholar 

  15. Barnes RB, Rosenfield RL. The polycystic ovary syndrome: pathogenesis and treatment. Ann Intern Med 1989; 110(5): 386–99

    PubMed  CAS  Google Scholar 

  16. Michelmore KF, Baien AH, Dunger DB, et al. Polycystic ovaries and associated clinical and biochemical features in young women. Clin Endocrinol (Oxf) 1999; 51: 779–86

    Article  CAS  Google Scholar 

  17. Baumann EE, Rosenfield RL. Polycystic ovary syndrome in adolescence. Endocrinologist 2002; 1: 333–48

    Article  Google Scholar 

  18. Ibáñez L, Valls C, Ferrer A, et al. Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism. J Clin Endocrinol Metab 2001; 86: 3595–8

    Article  PubMed  Google Scholar 

  19. Meirow D, Yossepowitch O, Rosier A, et al. Insulin resistant and non-resistant polycystic ovary syndrome represent two clinical and endocrinological subgroups. Hum Reprod 1995; 10: 1951–6

    PubMed  CAS  Google Scholar 

  20. Legro RS. Insulin resistance in polycystic ovary syndrome: treating a phenotype without a genotype. Mol Cell Endocrinol 1998; 145(1-2): 103–10

    Article  PubMed  CAS  Google Scholar 

  21. Acién P, Querada F, Matallín P, et al. Insulin, androgens, and obesity in women with and without polycystic ovary syndrome: a heterogeneous group of disorders. Fertil Steril 1999; 72: 32–40

    Article  PubMed  Google Scholar 

  22. Carmina E, Lobo RA. Do hyperandrogenic women with normal menses have polycystic ovary syndrome? Fertil Steril 1999; 71(2): 319–22

    Article  PubMed  CAS  Google Scholar 

  23. Gambineri A, Pelusi C, Manicardi E, et al. Glucose intolerance in a large cohort of Mediterranean women with polycystic ovary syndrome: phenotype and associated factors. Diabetes 2004; 53: 2353–8

    Article  PubMed  CAS  Google Scholar 

  24. Ehrmann DA, Rosenfield RL, Barnes RB, et al. Detection of functional ovarian hyperandrogenism in women with androgen excess, N Engl J Med 1992; 327: 157–62

    Article  PubMed  CAS  Google Scholar 

  25. Legro RS, Driscoll D, Strauss III JF, et al. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome, Proc Natl Acad Sci USA 1998; 95(25): 14956–60

    Article  PubMed  CAS  Google Scholar 

  26. Battaglia C, Regnani G, Mancini F, et al. Polycystic ovaries in childhood: a common finding in daughters of PCOS patients: a pilot study. Hum Reprod 2002; 17: 771–6

    Article  PubMed  Google Scholar 

  27. Jahanfar S, Eden JA, Warren P,et al. A twin study of polycystic ovary syndrome. Fertil Steril 1995; 63: 478–86

    PubMed  CAS  Google Scholar 

  28. The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41–7

    Article  Google Scholar 

  29. Dunaif A. Hyperandrogenic anovulation (PCOS): a unique disorder of insulin action associated with an increased risk of non-insulin-dependent diabetes mellitus. Am J Med 1995; 98(1A): 33S

    Article  PubMed  CAS  Google Scholar 

  30. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18: 774–800

    Article  PubMed  CAS  Google Scholar 

  31. Fox R, Ryan A. Polycystic ovary syndrome: not ovarian, not simple, unkind. Hum Fertil (Camb) 2002; 5(1): S28–32

    Article  Google Scholar 

  32. Achard C, Thiers J. Le virilisme pilaire et son association à l’insuffisance glycolytique (diabete des femmes à barbe). Bull Acad Natl Med 1921; 86: 51–64

    Google Scholar 

  33. Kahn CR, Flier JS, Bar RS, et al. The syndromes of insulin resistance and acanthosis nigricans: insulin receptor disorders in man. N Engl J Med 1976; 294: 739–45

    Article  PubMed  CAS  Google Scholar 

  34. Burghen GA, Givens JR, Kitabchi AE. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 1980; 5: 113–6

    Article  Google Scholar 

  35. Poretsky L. On the paradox of insulin-induced hyperandrogenism in insulin-resistant states. Endocr Rev 1991; 12(1): 3–13

    Article  PubMed  CAS  Google Scholar 

  36. Dunaif A, Segal KR, Shelley DR, et al. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 1992; 41: 1257–66

    Article  PubMed  CAS  Google Scholar 

  37. Ehrmann DA, Barnes RB, Rosenfield RL, et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999; 22: 141–6

    Article  PubMed  CAS  Google Scholar 

  38. Chang RJ, Nakamura RM, Judd HL, et al. Insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab 1983; 57: 356–9

    Article  PubMed  CAS  Google Scholar 

  39. Dunaif A, Segal KR, Futterweit W, et al. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989; 38: 1165–74

    Article  PubMed  CAS  Google Scholar 

  40. Barbieri RL, Makris A, Ryan KJ. Effects of insulin on steroidogenesis in cultured porcine ovarian theca. Fertil Steril 1983; 40(2): 237–41

    PubMed  CAS  Google Scholar 

  41. Dunaif A. Insulin action in the polycystic ovary syndrome. Endocrinol Metab Clin North Am 1999; 28(2): 341–59

    Article  PubMed  CAS  Google Scholar 

  42. Cara JF, Rosenfield R. Insulin-like growth factor 1 and insulin potentiate luteinizing hormone induced androgen synthesis by rat ovarian thecal-interstitial cells. Endocrinology 1988; 123: 733–9

    Article  PubMed  CAS  Google Scholar 

  43. Nestler JE, Powers LP, Matt DW, et al. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1991; 72(1): 83–9

    Article  PubMed  CAS  Google Scholar 

  44. De Leo V, la Marca A, Petraglia F. Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev 2003; 24: 633–67

    Article  PubMed  CAS  Google Scholar 

  45. Pierpoint T, McKeigue PM, Isaacs AJ, et al. Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol 1998; 51: 581–6

    Article  PubMed  CAS  Google Scholar 

  46. Cibula D, Cífková R, Fanta M, et al. Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. Hum Reprod 2000; 15: 785–9

    Article  PubMed  CAS  Google Scholar 

  47. Wild S, Pierpoint T, McKeigue P, et al. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf) 2000; 52: 595–600

    Article  CAS  Google Scholar 

  48. Legro RS, Kunselman AR, Dodson WC, et al. Prevalence and predictors of the risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome. J Clin Endocrinol Metab 1999; 84: 165–9

    Article  PubMed  CAS  Google Scholar 

  49. Ovalle F, Azziz R. Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril 2002; 77: 1095–105

    Article  PubMed  Google Scholar 

  50. Dahlgren E, Janson PO, Johansson S, et al. Polycystic ovary syndrome and risk for myocardial infarction: evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand 1992; 7: 599–604

    Article  Google Scholar 

  51. Després JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952–7

    Article  PubMed  Google Scholar 

  52. Guzick DS, Talbott EO, Sutton-Tyrrell K, et al. Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case-control study. Am J Obstet Gynecol 1996; 17: 1224–32

    Article  Google Scholar 

  53. Mather KJ, Kwan F, Corenblum B. Hyperinsulinemia in polycystic ovary syndrome correlates with increased cardiovascular risk independent of obesity. Fertil Steril 2000; 73: 150–6

    Article  PubMed  CAS  Google Scholar 

  54. Atiomo WU, Bates SA, Condon JE, et al. The plasminogen activator system in women with polycystic ovary syndrome. Fertil Steril 1998; 69: 236–41

    Article  PubMed  CAS  Google Scholar 

  55. Atiomo WU, Fox R, Condon JE, et al. Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf) 2000; 52: 487–92

    Article  CAS  Google Scholar 

  56. Pirwany IR, Fleming R, Greer IA, et al. Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters. Clin Endocrinol (Oxf) 2001; 54: 447–53

    Article  CAS  Google Scholar 

  57. Talbott EO, Guzick DS, Sutton-Tyrrell K, et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 2000; 20: 2414–21

    Article  PubMed  CAS  Google Scholar 

  58. Reaven GM. Syndrome X: 6 years later. J Intern Med 1994; 236Suppl. 736: 13–22

    Google Scholar 

  59. Dokras A, Bochner M, Hollinrake E, et al. Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet Gynecol 2005 Jul; 106(1): 131–7

    Article  PubMed  Google Scholar 

  60. Hendarson CW. PCOS may lead to early onset of atherosclerosis even among thin women. Womens Health Wkly 2000; 11: 2–3

    Google Scholar 

  61. Lakhani K, Hardiman P, Seifalian AM. Intima-media thickness of elastic and muscular arteries of young women with polycystic ovaries. Atherosclerosis 2004; 175: 353–9

    Article  PubMed  CAS  Google Scholar 

  62. Paradisi G, Steinberg HO, Shepard MK, et al. Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003 Feb; 88(2): 576–80

    Article  PubMed  CAS  Google Scholar 

  63. Hube F, Birgel M, Lee YM, et al. Expression pattern of tumour necrosis factor receptors in subcutaneous and omental human adipose tissue: role of obesity and non-insulin-dependent diabetes mellitus. Eur J Clin Invest 1999; 29: 672–8

    Article  PubMed  CAS  Google Scholar 

  64. Yudkin JS, Kumari M, Humphries SE, et al. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000; 148: 209–14

    Article  PubMed  CAS  Google Scholar 

  65. Campos SP, Baumann H. Insulin is a prominent modulator of the cytokinestimulated expression of acute-phase plasma protein genes. Mol Cell Biol 1992; 12: 1789–97

    PubMed  CAS  Google Scholar 

  66. Pasceri V, Cheng JS, Willerson JT, et al. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001; 103: 2531–4

    Article  PubMed  CAS  Google Scholar 

  67. Kelly CC, Lyall H, Petrie JR, et al. Low grade chronic inflammation in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2001; 86: 2453–5

    Article  PubMed  CAS  Google Scholar 

  68. Boulman N, Leiba LR, Shachar S, et al. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab 2004; 89: 2160–5

    Article  PubMed  CAS  Google Scholar 

  69. Villuendas G, San Millan JL, Sancho J, et al. The −597 G→A and −174 G↦C polymorphisms in the promoter of the interleukin 6 gene (IL6) are associated with hyperandrogenism J Clin Endocrinol Metab 2002; 87: 1134–41

    CAS  Google Scholar 

  70. González F, Thusu K, Rahman EH, et al. Elevated serum levels of tumor necrosis factor a in normal-weight women with polycystic ovary syndrome. Metabolism 1999; 48: 437–41

    Article  PubMed  Google Scholar 

  71. Escobar-Morreale HF, Botella-Carretero JI, Villuendas G, et al. Serum interleukin-18 concentrations are increased in the polycystic ovary syndrome: relationship to insulin resistance and to obesity. J Clin Endocrinol Metab 2004; 89: 806–11

    Article  PubMed  CAS  Google Scholar 

  72. Fain JN, Bahouth SW, Madan AK. TNF release by the nonfat cells of human adipose tissue. Int J Obes 2004; 28: 616–22

    Article  CAS  Google Scholar 

  73. Sayin N, Gücer F, Balkanli-Kaplan P, et al. Elevated serum TNF-α levels in normal-weight women with polycystic ovaries or the polycystic ovary syndrome. J Reprod Med 2003; 48: 165–70

    PubMed  CAS  Google Scholar 

  74. Gonzalez F, Minium J, Rote NS, et al. Hyperglycemia alters tumor necrosis factor-α release from mononuclear cells in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90(9): 5336–42

    Article  PubMed  CAS  Google Scholar 

  75. Colilla S, Cox NJ, Ehrmann DA. Heritability of insulin secretion and insulin action in women with polycystic ovary syndrome and their first degree relatives. J Clin Endocrinol Metab 2001; 86: 2027–31

    Article  PubMed  CAS  Google Scholar 

  76. Ciaraldi TP, El-Roeiy A, Madar Z, et al. Cellular mechanisms of insulin resistance in polycystic ovarian syndrome. J Clin Endocrinol Metab 1992; 75: 577–83

    Article  PubMed  CAS  Google Scholar 

  77. Dunaif A, Wu X, Lee A, et al. Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS). Am J Physiol Endocrinol Metab 2001; 281: E392–9

    PubMed  CAS  Google Scholar 

  78. Dunaif A, Xia J, Book CB, et al. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle: a potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest 1995; 96: 801–10

    Article  PubMed  CAS  Google Scholar 

  79. Book CB, Dunaif A. Selective insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1999; 84: 3110–6

    Article  PubMed  CAS  Google Scholar 

  80. Corbould A, Kim YB, Youngren JF, et al. Insulin resistance in the skeletal muscle of women with PCOS involves intrinsic and acquired defects in insulin signaling. Am J Physiol Endocrinol Metab 2005; 288(5): E1047–54

    Article  PubMed  CAS  Google Scholar 

  81. Legro RS, Driscoll D, Strauss III J, et al. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci U S A 1998; 95: 14956–60

    Article  PubMed  CAS  Google Scholar 

  82. Norman RJ, Masters S, Hague W. Hyperinsulinemia is common in family members of women with polycystic ovary syndrome. Fertil Steril 1996; 66: 942–7

    PubMed  CAS  Google Scholar 

  83. Legro RS, Bentley-Lewis R, Driscoll D, et al. Insulin resistance in the sisters of women with polycystic ovary syndrome: association with hyperandrogenemia rather than menstrual irregularity. J Clin Endocrinol Metab 2002; 7: 2128–33

    Article  Google Scholar 

  84. Yidiz BO, Yarali H, Oguz H, et al. Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome. Clin Endocrinol Metab 2003; 88: 2031–6

    Article  CAS  Google Scholar 

  85. Ehrman DA, Kasza K, Azziz R, et al. Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90: 66–71

    Article  CAS  Google Scholar 

  86. Sam S, Legor RS, Bentley-Lewis R, et al. Dyslipidemia and metabolic syndrome in the sisters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005 Aug; 90: 4797–802

    Article  PubMed  CAS  Google Scholar 

  87. Nestler JE, Barlascini CO, Matt DW, et al. Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 1989; 68(6): 1027–32

    Article  PubMed  CAS  Google Scholar 

  88. Legro RS, Castracane VD, Kauffman RP. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynecol Surv 2004; 59: 141–54

    Article  PubMed  Google Scholar 

  89. Kiddy DS, Hamilton-Fairley D, Bush A, et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol 1992; 36: 105–11

    Article  CAS  Google Scholar 

  90. Kiddy DS, Hamilton-Fairley D, Seppala M, et al. Diet-induced changes in sex hormone binding globulin and free testosterone in women with normal or polycystic ovaries: correlation with serum insulin and insulin-like growth factor-I. Clin Endocrinol (Oxf) 1989; 31: 757–63

    Article  CAS  Google Scholar 

  91. Gambineri A, Pelusi C, Genghini S, et al. Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2004; 60: 241–9

    Article  CAS  Google Scholar 

  92. Sattar N, Hopkinson ZE, Greer IA. Insulin-sensitising agents in polycystic ovary syndrome. Lancet 1998; 351(9099): 305–7

    Article  PubMed  CAS  Google Scholar 

  93. Nestler JE. Should patients with polycystic ovarian syndrome be treated with metformin? An enthusiastic endorsement. Hum Reprod 2002; 17: 1950–98

    Article  PubMed  CAS  Google Scholar 

  94. Nestler JE, Stovall D, Akhter N, et al. Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome. Fertil Steril 2002; 77: 209–15

    Article  PubMed  Google Scholar 

  95. Loverro GF, Lorusso G, De Pergola G, et al. Clinical and endocrinological effects of 6 months of metformin treatment in young hyperinsulinemic patients affected by polycystic ovary syndrome. Gynecol Endocrinol 2002; 16: 3217–24

    Google Scholar 

  96. Ehrmann DA, Schneider DJ, Sobel BE, et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82(7): 2108–16

    Article  PubMed  CAS  Google Scholar 

  97. Hasegawa I, Murakawa H, Suzuki M, et al. Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome. Fertil Steril 1999; 71(2): 323–7

    Article  PubMed  CAS  Google Scholar 

  98. Taylor AE. Insulin-lowering medications in polycystic ovary syndrome. Obstet Gynecol Clin North Am 2000; 27: 583–95

    Article  PubMed  CAS  Google Scholar 

  99. Glueck CJ, Streicher P, Wang P. Treatment of polycystic ovary syndrome with insulin-lowering agents. Expert Opin Pharmacother 2002; 3: 1177–89

    Article  PubMed  CAS  Google Scholar 

  100. Crosignani PG, Colombo M, Vegetti W, et al. Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet. Hum Reprod 2003; 18: 1928–32

    Article  PubMed  Google Scholar 

  101. Moran LJ, Noakes M, Clifton PM, et al. Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88: 812–9

    Article  PubMed  CAS  Google Scholar 

  102. Lord JM, Flight IHK, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 2003; 327: 951–6

    Article  PubMed  CAS  Google Scholar 

  103. Lord JM, Flight IHK, Norman RJ. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, d-chiro-inositol) for polycystic ovary syndrome. Chichester: John Wiley & Sons, Ltd, 2004

    Google Scholar 

  104. Stamets K, Taylor DS, Kunselman A, et al. A randomized trial of the effects of two types of short-term hypocaloric diets on weight loss in women with polycystic ovary syndrome. Fertil Steril 2004; 81: 630–7

    Article  PubMed  CAS  Google Scholar 

  105. Hoeger KM, Kochman L, Wixom N, et al. A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertil Steril 2004; 82: 421–9

    Article  PubMed  CAS  Google Scholar 

  106. Barbieri RL, Gargiulo AR. Metformin for the treatment of the polycystic ovary syndrome. Minerva Ginecol 2004; 56: 63–79

    PubMed  CAS  Google Scholar 

  107. Seli E, Duleba AJ. Treatment of PCOS with metformin and other insulin-sensitizing agents. Curr Diab Rep 2004; 4(1): 69–75

    Article  PubMed  Google Scholar 

  108. Norman RJ, Noakes M, Wu R, et al. Improving reproductive performance in overweight/obese women with effective weight management. Hum Reprod Update 2004; 10: 267–80

    Article  PubMed  Google Scholar 

  109. Clark AM, Ledger W, Galletly C, et al. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum Reprod 1995; 10: 2705–12

    Article  PubMed  CAS  Google Scholar 

  110. Kidson W. Polycystic ovary syndrome: a new direction in treatment. Med J Aust 1998; 169: 537–40

    PubMed  CAS  Google Scholar 

  111. Jakubowicz DJ, Nestler JE. 17 alpha-hydroxyprogesterone responses to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome offer dietary weight loss. J Clin Endocrinol Metab 1997; 82: 556–60

    Article  PubMed  CAS  Google Scholar 

  112. Pasquali R, Antenucci D, Casimirri F, et al. Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. J Clin Endocrinol Metab 1989; 68: 173–9

    Article  PubMed  CAS  Google Scholar 

  113. Andersen P, Seljeflot I, Abdelnoor M, et al. Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome. Metabolism 1995; 44: 611–6

    Article  PubMed  CAS  Google Scholar 

  114. Van Dam EW, Roelfsema F, Veldhuis JD, et al. Increase in daily LH secretion in response to short-term calorie restriction in obese women with PCOS. Am J Physiol Endocrinol Metab 2002; 282: E865–72

    PubMed  Google Scholar 

  115. Esposito K, Pontillo A, Di Palo C, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003; 289: 1799–804

    Article  PubMed  CAS  Google Scholar 

  116. Liu S, Willett WC, Manson JE, et al. Relation between changes in intakes of dietary fiber and grain products and changes in weight and development of obesity among middle-aged women. Am J Clin Nutr 2003; 78: 920–7

    PubMed  CAS  Google Scholar 

  117. Foster GD, Wyatt HR, Hill JO, et al. A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med 2003; 348: 2082–90

    Article  PubMed  CAS  Google Scholar 

  118. Goodyear LJ, Kahn BB. Exercise, glucose transport, and insulin sensitivity. Annu Rev Med 1998; 49: 235–61

    Article  PubMed  CAS  Google Scholar 

  119. Kashyap S, Wells GA, Rosenwaks Z. Insulin-sensitizing agents as primary therapy for patients with polycystic ovarian syndrome. Hum Reprod 2004; 19: 2474–83

    Article  PubMed  CAS  Google Scholar 

  120. Lebovitz HE. Oral antidiabetic agents. Med Clin North Am 2004; 88: 847–63

    Article  PubMed  CAS  Google Scholar 

  121. Ehrmann DA, Cavaghan MK, Imperial J, et al. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82: 524–30

    Article  PubMed  CAS  Google Scholar 

  122. Ghazeeri G, Kutteh WH, Bryer-Ash M, et al. Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 2003; 79: 562–6

    Article  PubMed  Google Scholar 

  123. Glueck CJ, Moreira A, Goldenberg N, et al. Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin. Hum Reprod 2003; 18: 1618–25

    Article  PubMed  CAS  Google Scholar 

  124. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996; 45: 1661–9

    Article  PubMed  CAS  Google Scholar 

  125. Mudaliar S, Henry RR. New oral therapies for type 2 diabetes mellitus: the glitazones or insulin sensitizers. Annu Rev Med 2001; 52: 239–57

    Article  PubMed  CAS  Google Scholar 

  126. Inzucchi SE, Maggs DG, Spollett GR, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998; 26: 867–72

    Article  Google Scholar 

  127. Seedorf U, Assmann G. The role of PPAR alpha in obesity. Nutr Metab Cardiovasc Dis 2001; 11: 189–94

    PubMed  CAS  Google Scholar 

  128. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307–12

    Article  PubMed  CAS  Google Scholar 

  129. U.S. Department of Health and Human Services. Rezulin to be withdrawn from the market. HHS News 2000 Mar 21; P00-8

  130. Frias JP, Yu JG, Kruszynska YT, et al. Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects. Diabetes Care 2000; 23: 64–9

    Article  PubMed  CAS  Google Scholar 

  131. Nolan JJ, Ludvik B, Beerdsen P, et al. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994; 331: 1188–93

    Article  PubMed  CAS  Google Scholar 

  132. Maggs DG, Burant CF, Buchanan TA, et al. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. Ann Intern Med 1998; 128: 176–85

    PubMed  CAS  Google Scholar 

  133. Petersen KF, Krssak M, Inzucchi S, et al. Mechanism of troglitazone action in type 2 diabetes. Diabetes 2000; 49: 827–31

    Article  PubMed  CAS  Google Scholar 

  134. Thyer C, Brzyski R, Easton C, et al. A comparison of the effect of metformin and rosiglitazone on insulin action and secretion in women with polycystic ovary syndrome. Fertil Steril 2002; 78(3 Suppl. 1): S105–6

    Article  Google Scholar 

  135. Romualdi D, Guido M, Ciampelli M, et al. Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. Hum Reprod 2003; 18: 1210–8

    Article  PubMed  CAS  Google Scholar 

  136. Brettenthaler N, De Geyter C, Huber PR, et al. Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004; 89: 3835–40

    Article  PubMed  CAS  Google Scholar 

  137. Belli SH, Graffigna MN, Oneto A, et al. Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome. Fertil Steril 2004; 81: 624–9

    Article  PubMed  CAS  Google Scholar 

  138. Sepilian V, Nagamani M. Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance. J Clin Endocrinol Metab 2005; 90: 60–5

    Article  PubMed  CAS  Google Scholar 

  139. Azziz R, Ehrmann D, Legro RS, et al. Troglitazone use in polycystic ovary syndrome. J Clin Endocrinol Metab 2001; 86: 5090–1

    Article  CAS  Google Scholar 

  140. Arlt W, Auchus RJ, Miller WL. Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3beta-hydroxysteroid dehydrogenase. J Biol Chem 2001; 276: 16767–71

    Article  PubMed  CAS  Google Scholar 

  141. Mitwally MF, Witchel SF, Casper RF. Troglitazone: a possible modulator of ovarian steroidogenesis. J Soc Gynecol Investig 2002; 9: 163–7

    Article  PubMed  CAS  Google Scholar 

  142. Dunaif A, Scott D, Finegood D, et al. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996; 81: 3299–306

    Article  PubMed  CAS  Google Scholar 

  143. Azziz R, Ehrmann DA, Legro RS, et al. PCOS/Troglitazone Study Group: troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome. Fertil Steril 2003; 79: 927–37

    Article  Google Scholar 

  144. Mitwally MFM, Kusen NK, Yalcinkaya TM. High ovulatory rates with use of troglitazone in clomiphene-resistant women with polycystic ovary syndrome. Human Reprod 1999; 14(11): 2700–3

    Article  CAS  Google Scholar 

  145. Legro RS, Azziz R, Ehrmann D, et al. Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone. J Clin Endocrinol Metab 2003; 88: 5137–44

    Article  PubMed  CAS  Google Scholar 

  146. Ye JM, Doyle PJ, Iglesias MA, et al. Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-gamma activation. Diabetes 2001; 50: 411–7

    Article  PubMed  CAS  Google Scholar 

  147. GlaxoSmithKline Pharmaceuticals. Avandia (rosiglitazone maleate) [package insert]. Philadelphia (PA): GlaxoSmithKline Pharmaceuticals, 2000

    Google Scholar 

  148. Kalyoncu NI, Yaris F, Ulka C, et al. A case of rosiglitazone exposure in the second trimester of pregnancy. Reprod Toxicology 2005; 19: 563–4

    Article  CAS  Google Scholar 

  149. Zheng Z, Li M, Lin Y, et al. Effect of rosiglitazone on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Zhonghua Fu Chan Ke Za Zhi 2002; 37: 271–3

    PubMed  Google Scholar 

  150. Baillargeon JP, Jakubowicz DJ, Iuorno MJ, et al. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril 2004; 82: 893–902

    Article  PubMed  CAS  Google Scholar 

  151. Dereli D, Dereli T, Bayraktar F, et al. Endocrine and metabolic effects of rosiglitazone in non-obese women with polycystic ovary disease. Endocr J 2005; 52: 299–308

    Article  PubMed  CAS  Google Scholar 

  152. Cataldo N, Abbasi F, Mclaughlin T, et al. Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone. Fertil Steril 2001; 76: 1057–9

    Article  PubMed  CAS  Google Scholar 

  153. Cataldo A, Abbasi F, McLaughlin TL, et al. Metabolic and ovarian effects of rosiglitazone treatment for 12 weeks in insulin-resistant women with polycystic ovary syndrome. Hum Reprod 2006 Jan; 21: 109–20

    Article  PubMed  CAS  Google Scholar 

  154. Shobokshi A, Shaarawy M. Correction of insulin resistance and hyperandrogenism in polycystic ovary syndrome by combined rosiglitazone and clomiphene citrate therapy. J Soc Gynecol Investig 2003 Feb; 10(2): 99–104

    Article  PubMed  CAS  Google Scholar 

  155. Tarkun I, Cetinarslan B, Turemen E, et al. Effect of rosiglitazone on insulin resistance, C-reactive protein and endothelial function in non-obese young women with polycystic ovary syndrome. Eur J Endocrinol 2005; 153(1): 115–21

    Article  PubMed  CAS  Google Scholar 

  156. Lemay A, Dodin S, Turcot L, et al. Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance. Hum Reprod 2006 Jan; 21: 121–8

    Article  PubMed  CAS  Google Scholar 

  157. Gillies PS, Dunn CJ. Pioglitazone. Drugs 2000; 60: 333–43

    Article  PubMed  CAS  Google Scholar 

  158. Takeda Pharmaceuticals America, Inc. Actos (pioglitazone hydrochloride) [package insert]. Lincolnshire (IL): Takeda Pharmaceuticals America, Inc, 2000

    Google Scholar 

  159. Guido M, Romualdi D, Suriano R, et al. Effect of pioglitazone treatment on the adrenal androgen response to corticotrophin in obese patients with polycystic ovary syndrome. Hum Reprod 2004; 19: 534–9

    Article  PubMed  CAS  Google Scholar 

  160. Coffler MS, Patel K, Dahan MH, et al. Enhanced granulosa cell responsiveness to follicle-stimulating hormone during insulin infusion in women with polycystic ovary syndrome treated with pioglitazone. J Clin Endocrinol Metab 2003; 88: 5624–31

    Article  PubMed  CAS  Google Scholar 

  161. Ortega-Gonzalez C, Luna S, Hernandez L, et al. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005 Mar; 90(3): 1360–5

    Article  PubMed  CAS  Google Scholar 

  162. Ortega-Gonzalez C, Cardoza L, Coutino B, et al. Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome. J Endocrinol 2005 Jan; 184(1): 233–9

    Article  PubMed  CAS  Google Scholar 

  163. Ben-Haroush A, Yogev Y, Fisch B. Insulin resistance and metformin in polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2004; 115: 125–33

    Article  PubMed  CAS  Google Scholar 

  164. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003; 108: 2941–8

    Article  PubMed  Google Scholar 

  165. Fonseca V, Rosenstock J, Patwardhan R, et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000; 283: 1695–702

    Article  PubMed  CAS  Google Scholar 

  166. Day C. Thiazolidinediones: a new class of antidiabetic drugs. Diabet Med 1999; 16: 179–92

    Article  PubMed  CAS  Google Scholar 

  167. De Souza CJ, Eckhardt M, Gagen K, et al. Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes 2001; 50: 1863–71

    Article  PubMed  Google Scholar 

  168. Shimizu H, Tsuchiya T, Sato N, et al. Troglitazone reduces plasma leptin concentration but increases hunger in NIDDM patients. Diabetes Care 1998; 21: 1470–4

    Article  PubMed  CAS  Google Scholar 

  169. Mayerson AB, Hundal RS, Dufour S, et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002; 51: 797–802

    Article  PubMed  CAS  Google Scholar 

  170. Virtanen KA, Hallsten K, Parkkola R, et al. Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects. Diabetes 2003; 52: 283–90

    Article  PubMed  CAS  Google Scholar 

  171. DeFronzo R. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131: 281–303

    PubMed  CAS  Google Scholar 

  172. Carey DG, Jenkins AB, Campbell LV, et al. Abdominal fat and insulin resistance in normal and overweight women: direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes 1996; 45: 633–8

    Article  PubMed  CAS  Google Scholar 

  173. Kelly IE, Han TS, Walsh K, et al. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 1999; 22: 288–93

    Article  PubMed  CAS  Google Scholar 

  174. Banerji M, Lebovitz H, Dugbartey M. Rosiglitazone selectively increases subcutaneous but not visceral adipose tissue mass in type 2 diabetes mellitus [abstract]. Diabetes 2001; 50Suppl. 2: A90

    Google Scholar 

  175. Mori Y, Murokawa Y, Okada Y, et al. Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care 1999; 22: 908–12

    Article  PubMed  CAS  Google Scholar 

  176. Bogacka I, Xie H, Bray GA, et al. The effect of pioglitazone on peroxisome proliferator-activated receptor-γ target genes related to lipid storage in vivo. Diabetes Care 2004; 27: 1660–7

    Article  PubMed  CAS  Google Scholar 

  177. Crave JC, Fimbel S, Lejeune H, et al. Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women. J Clin Endocrinol Metab 1995; 80: 2057–62

    Article  PubMed  CAS  Google Scholar 

  178. Moghetti P, Castello R, Negri C, et al. Meformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000; 85: 139–46

    Article  PubMed  CAS  Google Scholar 

  179. Watkins PM, Whitcomb RW. Hepatic dysfunction associated with troglitazone. N Engl J Med 1998; 338: 916–7

    Article  PubMed  CAS  Google Scholar 

  180. Norman RJ, Masters L, Milner CR, et al. Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum Reprod 2001; 16: 1995–8

    Article  PubMed  CAS  Google Scholar 

  181. Parke-Davis. Rezulin prescribing information. Morris Plains (NJ): Parke-Davis, Dec 1997

  182. Bell DS. Beta-cell rejuvenation with thiazolidinediones. Am J Med 2003; 115Suppl. 8A: 20S–3S

    Article  PubMed  CAS  Google Scholar 

  183. Augstein P, Dunger A, Heinke P, et al. Prevention of autoimmune diabetes in NOD mice by troglitazone is associated with modulation of ICAM-1 expression on pancreatic islet cells and IFN-gamma expression in splenic T cells. Biochem Biophys Res Commun 2003; 304: 378–84

    Article  PubMed  CAS  Google Scholar 

  184. The Diabetes Prevention Program Research Group. Prevention of type 2 diabetes with troglitazone in the diabetes prevention program. Diabetes 2005; 54: 1150–6

    Article  Google Scholar 

  185. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 2002; 51: 2796–803

    Article  PubMed  CAS  Google Scholar 

  186. Ovalle F, Bell DS. Clinical evidence of thiazolidinedione-induced improvement of pancreatic beta-cell function in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2002; 4: 56–9

    Article  PubMed  CAS  Google Scholar 

  187. Juhl CB, Hollingdal M, Porksen N, et al. Influence of rosiglitazone treatment on beta-cell function in type 2 diabetes: evidence of an increased ability of glucose to entrain high-frequency insulin pulsatility. J Clin Endocrinol Metab 2003; 88: 3794–800

    Article  PubMed  CAS  Google Scholar 

  188. Xiang AH, Peters RK, Kjos SL, et al. Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 2006; 55: 517–22

    Article  PubMed  CAS  Google Scholar 

  189. Boyle PJ. What are the effects of peroxisome proliferator-activated receptor agonists on adiponectin, tumor necrosis factor-alpha, and other cytokines in insulin resistance? Clin Cardiol 2004; 27(7 Suppl. 4): IV11–6

    PubMed  Google Scholar 

  190. Parulkar AA, Pendergrass ML, Granda-Ayala R, et al. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 2001; 134: 61–71

    PubMed  CAS  Google Scholar 

  191. Miles PD, Romeo OM, Higo K, et al. TNF-α-induced insulin resistance in vivo and its prevention by troglitazone. Diabetes 1997; 46: 1678–83

    Article  PubMed  CAS  Google Scholar 

  192. Marx N, Kehrle B, Kohlhammer K, et al. PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res 2002; 90: 703–10

    Article  PubMed  CAS  Google Scholar 

  193. Derosa G, Cicero AF, Gaddi A, et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clin Ther 2004; 26: 744–54

    Article  PubMed  CAS  Google Scholar 

  194. Sidhu JS, Kaposzta Z, Markus HS, et al. Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol 2004; 24: 930–4

    Article  PubMed  CAS  Google Scholar 

  195. Takagi T, Yamamuro A, Tamita K, et al. Impact of troglitazone on coronary stent implantation using small stents in patients with type 2 diabetes mellitus. Am J Cardiol 2002; 89: 318–22

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Woman’s Health Research Institute, 9050 Airline Highway-Baton Rouge, Baton Rouge, Louisiana, 70810, USA

    Karen E. Elkind-Hirsch

Authors
  1. Karen E. Elkind-Hirsch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Karen E. Elkind-Hirsch.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Elkind-Hirsch, K.E. Thiazolidinediones for the Therapeutic Management of Polycystic Ovary Syndrome. Mol Diag Ther 5, 171–187 (2006). https://doi.org/10.2165/00024677-200605030-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00024677-200605030-00005

Keywords

Search

Navigation